These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37640023)

  • 1. Prevalence and Risk Factors of Metabolic Dysfunction-Associated Fatty Liver Disease with Renal Insufficiency in Overweight/Obese Adults.
    Shi A; Deng J; Ma J; Yang L; Tantai X; Wang Q; Chang D; Wang J; Guo X; Lu X; Shi H
    Obes Facts; 2023; 16(6):548-558. PubMed ID: 37640023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults.
    Liu J; Ayada I; Zhang X; Wang L; Li Y; Wen T; Ma Z; Bruno MJ; de Knegt RJ; Cao W; Peppelenbosch MP; Ghanbari M; Li Z; Pan Q
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e573-e582. PubMed ID: 33618024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential algorithm to stratify liver fibrosis risk in overweight/obese metabolic dysfunction-associated fatty liver disease.
    Lee CH; Lui DT; Li RH; Yuen MM; Fong CH; Leung AP; Chu JC; Mak LL; Lam TH; Woo J; Woo YC; Xu A; Tse HF; Tan KC; Cheung BM; Yuen MF; Lam KS
    Front Endocrinol (Lausanne); 2022; 13():1056562. PubMed ID: 36686469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea.
    Kim M; Yoon EL; Cho S; Lee CM; Kang BK; Park H; Jun DW; Nah EH
    Liver Int; 2022 Jul; 42(7):1536-1544. PubMed ID: 35338555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simple proxies of insulin resistance identify obese metabolic dysfunction-associated fatty liver disease subjects with advanced liver disease.
    Petralli G; Salvati A; Tricò D; Ricco G; Colombatto P; Brunetto MR; Solini A
    Diabetes Metab Res Rev; 2024 Feb; 40(2):e3736. PubMed ID: 37839068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease.
    Tanaka M; Mori K; Takahashi S; Higashiura Y; Ohnishi H; Hanawa N; Furuhashi M
    Nephrol Dial Transplant; 2023 Feb; 38(3):700-711. PubMed ID: 35612975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.
    Hu Q; Chen Y; Bao T; Huang Y
    Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic dysfunction-associated fatty liver disease in people living with HIV.
    Michel M; Labenz C; Armandi A; Kaps L; Kremer WM; Galle PR; Grimm D; Sprinzl M; Schattenberg JM
    Sci Rep; 2023 Jun; 13(1):9158. PubMed ID: 37280241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coexistence of Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease Is a More Potent Risk Factor for Ischemic Heart Disease.
    Miyamori D; Tanaka M; Sato T; Endo K; Mori K; Mikami T; Hosaka I; Hanawa N; Ohnishi H; Furuhashi M
    J Am Heart Assoc; 2023 Jul; 12(14):e030269. PubMed ID: 37421273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and associated factors of metabolic-associated fatty liver disease in overweight Finnish children and adolescents.
    Riekki H; Aitokari L; Kivelä L; Lahti S; Hiltunen P; Vuorela N; Huhtala H; Lakka TA; Kurppa K
    Front Endocrinol (Lausanne); 2023; 14():1090344. PubMed ID: 37409224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact on Prevalence of the Application of NAFLD/MAFLD Criteria in Overweight and Normal Weight Patients.
    Ordoñez-Vázquez AL; Juárez-Hernández E; Zuarth-Vázquez JM; Ramos-Ostos MH; Uribe M; Castro-Narro G; López-Méndez I
    Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Stroke With Metabolic Dysfunction-Associated Fatty Liver Disease With and Without CKD.
    Li Y; Wu S; Gao J; Zhang Y; Zuo Y; Tian X; Chen S; Xing A; Wang A; He Y
    Am J Kidney Dis; 2024 Apr; 83(4):477-488. PubMed ID: 37838141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease.
    Cheng KL; Wang SW; Cheng YM; Hsieh TH; Wang CC; Kao JH
    J Formos Med Assoc; 2024 Jan; 123(1):36-44. PubMed ID: 37491179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations.
    Feng Z; Zhao F; Wang Z; Tang X; Xie Y; Qiu L
    BMC Gastroenterol; 2024 Mar; 24(1):111. PubMed ID: 38491346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
    Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study.
    Chen YL; Li H; Li S; Xu Z; Tian S; Wu J; Liang XY; Li X; Liu ZL; Xiao J; Wei JY; Ma CY; Wu KN; Ran L; Kong LQ
    BMC Gastroenterol; 2021 May; 21(1):212. PubMed ID: 33971822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between metabolic dysfunction-associated fatty liver disease, chronic kidney disease, and abdominal obesity: a national retrospective cohort study.
    Cen C; Fan Z; Ding X; Tu X; Liu Y
    Sci Rep; 2024 Jun; 14(1):12645. PubMed ID: 38825630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The metabolic profiles and body composition of non-obese metabolic associated fatty liver disease.
    Zhang Y; Xiang L; Qi F; Cao Y; Zhang W; Lv T; Zhou X
    Front Endocrinol (Lausanne); 2024; 15():1322563. PubMed ID: 38375190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population.
    Lee H; Lim TS; Kim SU; Kim HC
    Hepatol Int; 2022 Dec; 16(6):1308-1317. PubMed ID: 36070124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic Dysfunction-Associated Fatty Liver Disease in Newly Diagnosed, Treatment-Naive Hypertensive Patients and Its Association with Cardiorenal Risk Markers.
    Theofilis P; Vordoni A; Tsimihodimos V; Kalaitzidis RG
    High Blood Press Cardiovasc Prev; 2023 Jan; 30(1):63-72. PubMed ID: 36626077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.